- Crisis Flares Anew as Lender CIT Seeks Federal Aid
- Producer Prices, Retail Sales Rise More Than Expected
- J&J Profit Falls, but Beats Forecasts; Shares Rise
- Small Businesses Brace for Slow Recovery: Survey
- Sun Micro Expects Earnings Results Below Estimates
- Geithner Sees Confidence Return, Supports Dollar
- Rattner Leaves US Autos Force, Probe Intensifies
- Govt Web Site: Madoff at Prison in Atlanta for Now
- US Mulling Mortgage Aid for Unemployed: Official
- Yoshikami: US and China — Mutual Dependency
- Auto Task Force Shifts Gears Without Rattner
- LPGA Can't Be Fixed Without Right Players Winning
- DST Buys Facebook Stock, Gives Employees Liquidity
- Your Best ‘Unemployment Trades’: Stock Pickers
- Options Target Netflix on Share Price Action
- Big Mac As Haute Cuisine
- Warren Buffett's Berkshire Hathaway Retreats from "Risky Business" - WSJ
- Where the Earnings Surprises Will Be: Strategists
- Goldman posts bigger-than-expected profit
- Nuance Communications acquires Jott
- Ahead of the Bell: Callaway Golf Co.
- Ahead of the Bell: Caterpillar
- Colonial BancGroup to sell 21 Nevada bank branches
- Proxy firms urge NRG holders to reject Exelon bid
- Safeway, union resume Colo. contract talks Tuesday
- NJ flight attendant arrested in Mich. fraud case
- Grand Rapids CC store tests textbook rentals
Text Size 
NEW BRUNSWICK, N.J. - Johnson & Johnson said Friday it completed its $893.7 million acquisition of Cougar Biotechnology Inc., a development stage company that is testing a potential treatment for prostate cancer.
Johnson & Johnson said about 20.1 million shares of Cougar were tendered in favor of its buyout offer, which represented 95.9 percent of the company's outstanding common stock.
Johnson & Johnson agreed to buy Cougar in May for $43 per share. Antitrust regulators signed off on the deal in June.
Los Angeles-based Cougar is conducting two late stage clinical trials of abiraterone acetate as a treatment for prostate cancer. It is also testing the drug against breast cancer, and has four other potential cancer drugs in various stages of clinical and preclinical development.
Cougar is now a wholly owned subsidiary of Johnson & Johnson, and will work with the Ortho Biotech Oncology Research and Development unit.
Johnson & Johnson shares rose 20 cents to close at $56.89 Friday.
(This version CORRECTS drug type from 'vaccine' to 'treatment')
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes